Status:
COMPLETED
Gastrointestinal Assessment of Three Novel RS4
Lead Sponsor:
University of Alberta
Conditions:
Diet Modification
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
The rates of chronic diseases like obesity, diabetes, and heart disease are rising across the world. This is especially true in industrialized countries like Canada and the USA. Even though there are ...
Detailed Description
The investigators propose a 4 week gastrointestinal (GI) assessment study to determine both the ideal dose and type of resistant starch to use in future studies. The following specific aims are offere...
Eligibility Criteria
Inclusion
- men and pre-menopausal, non-pregnant or non-lactating women
- non-vegetarian
- non-smoking
- alcohol intake ≤8 drinks/week
- ≤5 h/week of moderate-vigorous exercise
Exclusion
- acute or chronic GI illnesses, conditions, or issues
- history of GI surgical intervention
- chronic or current use of anti-hypertensive, lipid-lowering, anti-diabetic, analgesic, or laxative medications
- antibiotic treatment in the last 3 months
- use of fiber or probiotics supplements
- allergies or intolerances to fiber sources
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 22 2018
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03255603
Start Date
September 1 2017
End Date
December 22 2018
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alberta Diabetes Institute Clinical Research Unit
Edmonton, Alberta, Canada, T6G 2E1